Study: SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.Image Credit: Adao/ Shutterstock. This news article was a review of a ...

Study: Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study.Image Credit: Kateryna Kon/Shutterstock.com Background ...

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ... We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, ...

Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...

Can mosquitoes ever carry and spread SARS-CoV-2, the virus that causes COVID-19? We asked the experts to weigh in. ... you’ll need to read the label and select the proper active ingredient. ...

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. JAMA Network Open , 2022; 5 (10): e2238354 DOI: 10.1001/jamanetworkopen.2022.38354 Cite This Page : ...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (Covid-19), is responsible for the 2020 global pandemic. 1,2 Developing a vaccine that ...

Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to ...

A new study uncovers a surprising mechanism by which the SARS-CoV-2 virus, responsible for COVID-19, might cause immune-mediated tissue damage by targeting cells it has never infected.